Clinical trial
A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed/Refractory Multiple Myeloma
NCT05646836 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- March 21, 2023
- Completion date
- November 18, 2026
- Enrollment
- 90 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.